GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shukra Pharmaceuticals Ltd (BOM:524632) » Definitions » YoY Rev. per Sh. Growth

Shukra Pharmaceuticals (BOM:524632) YoY Rev. per Sh. Growth : -94.41% (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Shukra Pharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Shukra Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 was -94.41%.

Shukra Pharmaceuticals's Revenue per Share for the three months ended in Jun. 2024 was ₹0.72.


Shukra Pharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for Shukra Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shukra Pharmaceuticals YoY Rev. per Sh. Growth Chart

Shukra Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 109.30 -5.51 779.14 14.90 -54.69

Shukra Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 490.10 354.32 464.18 -91.59 -94.41

Shukra Pharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Shukra Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Mar. 2024 )
=(Revenue per Share (A: Mar. 2024 )-Revenue per Share (A: Mar. 2023 ))/ | Revenue per Share (A: Mar. 2023 ) |
=(17.027-37.577)/ | 37.577 |
=-54.69 %

Shukra Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2024 )
=(Revenue per Share (Q: Jun. 2024 )-Revenue per Share (Q: Jun. 2023 )) / | Revenue per Share (Q: Jun. 2023 )) |
=(0.72-12.876)/ | 12.876 |
=-94.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shukra Pharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Shukra Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Shukra Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Judges Bunglow Road, Bodakdev, 3rd Floor, Veer House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments; pharmaceutical and Laboratory. Its product portfolio includes antibiotics, antibiotics, quinolones, macrolides, anti-bacterial, anti-fungal, anti-malarial, anti-viral, antiprotozoal, anti-anthelmintic, anti-depressant, anti-manic, anti-emetic, beta-blockers, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.

Shukra Pharmaceuticals Headlines

No Headlines